Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study

BACKGROUND: Pyrotinib, a novel irreversible epidermal growth factor receptor 2 (EGFR)/HER2 dual tyrosine kinase inhibitor, has shown promising antitumor efficacy with tolerable toxicity in HER2‐positive metastatic breast cancer (MBC) in several clinical trials. However, the clinical trials do not us...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Sha, Chi, Yajing, Du, Yangyang, Wang, Jingfen, Shan, Changping, Yi, Weiwei, Shang, Mao, Man, Xiaochu, Tan, Qiaorui, Li, Huihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939137/
https://www.ncbi.nlm.nih.gov/pubmed/35894763
http://dx.doi.org/10.1002/cam4.5056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939137/
https://www.ncbi.nlm.nih.gov/pubmed/35894763
http://dx.doi.org/10.1002/cam4.5056

Ejemplares similares